Immunologic special forces: anti-pathogen cytotoxic T-lymphocyte immunotherapy following hematopoietic stem cell transplantation by Keller, Michael & Bollard, Catherine M.
Himmelfarb Health Sciences Library, The George Washington University
Health Sciences Research Commons
Pediatrics Faculty Publications Pediatrics
2014
Immunologic special forces: anti-pathogen
cytotoxic T-lymphocyte immunotherapy following
hematopoietic stem cell transplantation
Michael Keller
George Washington University
Catherine M. Bollard
George Washington University
Follow this and additional works at: https://hsrc.himmelfarb.gwu.edu/smhs_peds_facpubs
Part of the Immunology and Infectious Disease Commons, Pediatrics Commons, and the
Virology Commons
This Journal Article is brought to you for free and open access by the Pediatrics at Health Sciences Research Commons. It has been accepted for
inclusion in Pediatrics Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please
contact hsrc@gwu.edu.
APA Citation
Keller, M., & Bollard, C. M. (2014). Immunologic special forces: anti-pathogen cytotoxic T-lymphocyte immunotherapy following
hematopoietic stem cell transplantation. Immunotargets and Therapy, 3 (). http://dx.doi.org/10.2147/ITT.S40082
© 2014 Keller and Bollard. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
ImmunoTargets and Therapy 2014:3 97–106
ImmunoTargets and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
97
R e v I e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/ITT.S40082
Immunologic special forces: anti-pathogen 
cytotoxic T-lymphocyte immunotherapy following 
hematopoietic stem cell transplantation
Michael D Keller
Catherine M Bollard
Program for Cell enhancement and 
Technologies for Immunotherapy, 
Sheikh Zayed Institute for Pediatric 
Surgical Innovation, and Center for 
Cancer and Immunology Research, 
Children’s National Health System, 
washington, DC, USA
Correspondence: Catherine M Bollard 
Children’s National Health System,  
111 Michigan Ave Nw, 5th Floor,  
Main CRI, washington DC 20010, USA 
email cbollard@childrensnational.org
Abstract: Anti-pathogen adoptive T-cell immunotherapy has been proven to be highly effective 
in preventing or controlling viral infections following hematopoietic stem cell transplantation. 
Recent advances in manufacturing protocols allow an increased number of targeted pathogens, 
eliminate the need for viral transduction, broaden the potential donor pool to include pathogen-
naïve sources, and reduce the time requirement for production. Early studies suggest that 
anti-fungal immunotherapy may also have clinical benefit. Future advances include further 
broadening of the pathogens that can be targeted and development of T-cells with resistance to 
pharmacologic immunosuppression.
Keywords: immunotherapy, stem cell transplantation, T-cell, virus, fungus
Introduction
Since the advent of hematopoietic stem cell transplantation (HSCT), infections have 
remained a leading cause of morbidity and mortality in patients.1–4 Although advances 
in prophylactic therapy have reduced the early burden of viral and fungal infections, 
therapeutic options for breakthrough infections are complicated by toxicities, and for 
many viral infections there are no effective treatments.5–9 It has been well established 
that T-cell reconstitution is the most important factor in preventing viral infection fol-
lowing HSCT, and factors that influence the speed of T-cell recovery also impact the 
risk of viral infection in this period.2,3 As transplantation protocols have progressed to 
allow an increasing number of donor sources for transplantation, clinicians have had 
to balance the risks of graft versus host disease (GVHD) when using a T-cell replete 
graft versus delayed T-cell engraftment when using T-cell depletion or a naïve donor 
source such as cord blood.10,11
Given the importance of T-cells to antiviral immunity, use of donor lymphocyte 
infusions from the stem cell donor was discovered to be an effective salvage therapy 
for viral infections in HSCT recipients prior to T-cell recovery.12 However, the high 
rate of potentially fatal GVHD has relegated this treatment to a course of last resort. 
However, subsequent advances in immunobiology and culturing techniques have per-
mitted great progress in improving the safety and efficacy of cytotoxic T-lymphocyte 
(CTL) immunotherapy following HSCT. These include: an improved knowledge of 
conserved T-cell epitopes for various pathogens,13–15 improvements in ex vivo culture 
of T-cells and antigen-presenting cells,16–18 and rapid tests to evaluate the effector func-
tion and major histocompatibility complex (MHC) restriction of T-cells.19,20 In essence, 
CTL therapy allows clinicians to bypass the months required for T-cell engraftment 
and a subsequent primary immune response to a pathogen.
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Although trials utilizing antiviral CTLs represent the bulk 
of the studies to date, preclinical studies and early clinical 
trials of antifungal CTLs have also shown promise. Adoptive 
immunotherapy targeting tumor targets is also a burgeoning 
field, and has recently been reviewed.21 In this review, we 
summarize the methodologies and results of recent and cur-
rent trials of anti-pathogen CTL therapy, and recap recent 
preclinical advances that provide the framework for future 
CTL clinical studies.
Methodologies of CTL production
In CTL production protocols to date, two concepts are 
essential, ie, harnessing pathogen-specific T-cells, and the 
exclusion of alloreactive T-cells. This has been accomplished 
previously by either direct selection of donor cells, or stimu-
lation and ex vivo culture of donor T-cells from peripheral 
blood mononuclear cells (PBMCs).
Direct selection relies on cell sorting of donor PBMCs, 
usually after a short stimulation with the antigen of interest.22 
Selection can be achieved via multimer selection ( selecting 
for T-cells with a T-cell receptor of known antigen specificity), 
or by column selection of interferon-gamma- producing 
T-cells following a brief stimulation with an antigen of inter-
est (Figure 1). It has the advantage of a minimal time require-
ment for product manufacturing, and uses existing Good 
Manufacturing Practice-compliant sorting technologies. 
However, this technique requires leukapheresis of donors in 
order to collect sufficient cells for clinical use. Additionally, 
it requires that there be detectable pathogen-specific T-cells 
in the periphery, and thus it would not be a viable option for 
manufacturing of CTLs from pathogen-naïve donors nor for 
pathogens that induce a poor memory response. Multimer 
selection has the disadvantage of selecting only CD8+ T-cells 
of limited specificity and MHC restriction, which could allow 
pathogen evasion and possibly impair CTL persistence.23 
Additionally, previous studies have suggested that residual 
binding of multimers may impact T-cell function in vitro,24 
although the clinical impact of this effect is unclear. The 
recent development of reversible streptamer technology for 
selection bypasses this potential risk.25 Interferon-gamma 
selection allows inclusion of polyclonal antigen-specific 
CD4+ and CD8+ T-cells, and allows selection of a wider 
range of antigen-specific cells in the final product.
Alternatively, stimulation and ex vivo culture permits 
expansion of single or multiple pathogen-specific CTLs. 
Culture has several advantages over cell selection, includ-
ing generation of polyclonal CTLs, and expansion of cells 
to clinically useful volumes from a small volume of blood.26 
These advantages come at the expense of the culture and 
processing time required for CTL stimulation and expan-
sion, which can vary from 10 days to more than 3–4 weeks, 
depending on the donor source. Loss of the ability of cells to 
self-renew and impaired persistence in vivo has been a long-
standing concern with the use of prolonged ex vivo culture 
and expansion.27 However, clinical trials to date have dem-
onstrated prolonged persistence in spite of ex vivo culture.28 
Additionally, studies have demonstrated that ex vivo cultur-
ing with pathogen-specific stimuli eliminates alloreactivity,15 
likely due to cell death or inability to compete with pathogen-
specific T-cells, and residual alloreactivity in manufactured 
CTLs has been shown to be clinically insignificant.29 Early 
trials of CTL therapy depended on the use of virus-infected 
antigen-presenting cells, such as cytomegalovirus (CMV) 
lysates, CMV-infected fibroblasts, or Epstein Barr virus 
(EBV)-lymphoblastoid cell lines as a stimulant for expansion 
of donor-derived memory T-cells.30–32 Subsequent knowledge 
of dominant and highly conserved antigens such as CMV-
pp65 and Adenovirus (Adv) hexon and penton have permitted 
the replacement of live virus with antigen stimulation using 
either 15-mer peptide pools spanning viral proteins, or with 
transduction of DNA plasmids encoding viral antigens into 
antigen-presenting cells.33,34 New methods to rapidly grow 
and manipulate antigen-presenting cells have also enabled 
the use of a wider population of donors and targeting of a 
greater number of pathogens in a single CTL culture.16,35 
Optimization of cytokine cocktails for CTL culture has also 
allowed improved yields and targeted cellular phenotypes. 
In the recent rapid CTL protocol, interleukin (IL)-4 and IL-7 
were shown to produce CD4+ T-cells with a predominantly 
Th1 phenotype, whereas IL-2 and IL-15 seem to favor pro-
liferation of natural killer cells at the expense of T-cells.34 
Finally, studies have shown that central memory T-cells 
(characterized by expression of chemokine receptors CCR7, 
CD62L, and CD45RA) have superior persistence in vivo 
following adoptive transfer, and may be the ideal cell popula-
tion for adoptive immunotherapy.36,37 Consequently, studies 
using both selection and culture methods have demonstrated 
the development of central memory T-cells in the resulting 
CTL products.25,34
Clinical studies of anti-viral CTLs
Clinical studies utilizing cell selection
Cell selection has been used in several prior studies to treat 
patients following HSCT (Table 1). Cobbold et al pub-
lished the first clinical report in which CD8+ CMV-specific 
CTLs were isolated via tetramer selection.38 Complete or 
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partial clinical responses were achieved in nine patients 
who received infusions, although there were limited data 
on long-term persistence of infused CTLs. Feuchtinger 
et al utilized interferon-gamma column selection (Gamma 
capture assay; Miltenyi Biotec GmbH, Bergisch Gladbach, 
Germany) to produce CMV-CTL, resulting in partial to 
complete responses in 15 of 18 patients who were given a 
single dose.39 Peggs et al also used interferon-gamma selec-
tion to produce CMV-CTL, using either recombinant pp65 
or an overlapping peptide pool of 15-mers covering the pp65 
protein as stimulants.40 They were successful in protecting 
seven patients who were prophylactically treated, while 
in vivo expansion of CMV-CTLs was detected in 11 patients 
infused who had detectable CMV.40 Schmitt et al produced 
CMV-CTL from HSCT donors utilizing reversible strepta-
mers with MHC-restricted pp65 peptides.25 These products 
were used to successfully treat two patients who devel-
oped CMV reactivation during treatment of GVHD after 
HSCT.
Fewer clinical studies have been performed using 
these techniques to produce Adv-specific or EBV-specific 
CTL. Feuchtinger et al successfully produced Adv CTL by 
interferon-gamma selection for treatment of nine patients 
with treatment-refractory Adv infections.41 In vivo CTL 
expansion was demonstrated in five of six patients tested, 
and four patients had clearance of disease. Uhlin et al used 
Cell selection CTL culture
Column 
selection
~1 day >28 days
12 days
Or
Or Cytokines
Cytokines
Key
Viral vector or virus-
derived antigens
Antigen-presenting
cell
Pathogen-specific
T-cell
Alloreactive T-cell
MHC multimer
15-mer peptide
pool
IFN-γ
CD154
Antibody-conjugated
magnetic beads
Cord 
blood
Rapid
protocol
Multimer 
selection
Figure 1 Current Good Manufacturing Practice-compliant approaches for generation of antipathogen CTL products. 
Notes: Cell selection utilizes either multimers displaying a pathogen-derived peptide in the setting of a type I human leukocyte antigen molecule, or column selection utilizing 
ex vivo stimulation of T-cells with antigens followed by selection of interferon-gamma or CD154-expressing T-cells via antibody-coated immunomagnetic beads. ex vivo cell 
culture utilizes stimulation of T-cells by antigen-displaying antigen-presenting cells, which can be produced via antigenic peptide pools, viral transduction, or nucleofection. A 
rapid protocol can produce cytotoxic T-lymphocytes in 10–12 days from virus-seropositive donors after a single stimulation, whereas production of cytotoxic T-lymphocytes 
derived from cord blood requires three stimulations over a minimum of 28 days. 
Abbreviations: CTL, cytotoxic T-lymphocyte; IFN, interferon.
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human leukocyte antigen (HLA)-A2-specific pentamers 
to produce EBV-CTL from the haploidentical mother of 
a patient who underwent cord blood transplantation and 
subsequently developed EBV-induced post-transplant lym-
phoproliferative disease.42 A complete clinical response 
was obtained following two doses of CTLs. Moosmann 
et al treated six patients with EBV-induced post-transplant 
lymphoproliferative disease with EBV-CTL developed 
by interferon-gamma selection, and achieved complete 
responses in three patients with early disease, but no response 
in three patients with advanced, multiorgan disease.43 Of note, 
in all studies utilizing cell selection, no significant GVHD 
occurred, and clinical impacts were seen in spite of very low 
cell doses (,5×104 cells/kg in most studies).
Clinical studies utilizing cell culture
CTL production utilizing ex vivo cell culture has been the 
most common methodology to date, and accounts for the 
majority of patients treated in clinical trials of antipathogen 
adoptive immunotherapy (Table 1) over the past decade. 
 Walter et al were among the first to show that stimulation 
of donor PBMC by CMV extracts resulted in expansion of 
CMV-specific CTLs, which lost alloreactivity after several 
weeks of ex vivo culture but retained antiviral activity.32 There 
Table 1 Previous clinical trials of pathogen-specific T-cell therapy
Strategy Study Pathogen 
specificity
Donor Methodology Patient 
accrual
Centers 
(n)
Advantages/
disadvantages
Cell selection Cobbold et al38 CMv HSCT donor or  
third-party
Tetramer selection 9 1 Advantages
Rapid development 
Uses existing GMP 
compliant technology
Feuchtinger et al39 CMv HSCT donor or  
third-party
Interferon-gamma 
column selection
18 1
Peggs et al40 CMv HSCT donor Interferon-gamma 
column selection
18 1
Schmitt et al25 CMv HSCT donor Reversible Streptamer 
selection
2 1 Disadvantages
Limited repertoire with 
multimer use (low cell 
yield) 
Requires presence 
of pathogen-specific 
memory T-cells
Feuchtinger et al41 Adv HSCT donor Interferon-gamma 
column selection
9 1
Uhlin et al42 eBv Related  
haploidentical donor
Multimer selection 1 1
Moosman et al43 eBv HSCT donor Interferon-gamma 
column selection
6 1
Qasim et al54 Adv Third party Interferon-gamma 
column selection
1 1
 Uhlin et al52 CMv/eBv/Adv HSCT donor or  
third-party
Pentamer selection 8 1
Cell culture Perruccio et al69 CMv or  
Aspergillus
HSCT donor Stimulation of PBMC 
with CMv antigen or 
inactivated conidia
10 1 Advantages
Yields large number of 
polyclonal CTL 
Allows CTL 
development from 
pathogen-naïve donors
Leen et al17 CMv/eBv/Adv HSCT donor Ad5f35pp65  
transduced LCL
26 3
Micklethwaite et al45 CMv/Adv HSCT donor Ad5f35pp65  
transduced DC
12 1
Leen et al44 eBv/Adv HSCT donor Ad5f35 null  
transduced LCL
13 3
Barker et al50 eBv Third-party donor eBv-LCL stimulation 2 1 Disadvantages
Time-intensive 
(2–5 weeks)  
Regulatory requirements 
for GMP culturing
Rooney et al 201031 eBv HSCT donor Irradiated eBv-LCL 114 3
Balduzzi et al55 JCv HSCT donor Pepmix-pulsed PBMC 1 1
Leen et al51 CMv/eBv/Adv Third-party donor Ad5f35pp65  
transduced LCL
47 8
Gerdemann et al  
201372
CMv/eBv/Adv HSCT donor Nucleofection of DCs 12 2
Blythe et al 201346 CMv or  
CMv/Adv
HSCT donor NLv-peptide pulsing  
or Ad5f35pp65  
transduction of DCs
50 2
Abbreviations: Adv, adenovirus; CMv, cytomegalovirus; CTL, cytotoxic T-lymphocyte; DC, dendritic cells; eBv, epstein Barr virus; GMP, Good Manufacturing Practice; 
LCL, lymphoblastoid cell lines; HSCT, hematopoietic stem cell transplantation; PBMCs, peripheral blood mononuclear cells; JCv, John Cunningham virus.
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have been many advancements in ex vivo CTL culture since 
then, which have decreased both the manufacturing time and 
cost. Early notable strides involved the culture and manipu-
lation of antigen-presenting cells for CTL culture. Rooney 
et al successfully used irradiated EBV-lymphoblastoid cell 
lines (EBV-LCL) to generate EBV-specific CTL, which were 
effective as prophylaxis or treatment for EBV-induced post-
transplant lymphoproliferative disease in 114 patients.28,31 Of 
note, the first 26 patients received gene-marked CTLs, and 
follow-up studies showed persistence of the gene-marked 
cells as long as 105 months following infusion.
The development of clinical grade Adv vector Ad5f35pp65, 
which contains immunodominant CMV antigen pp65, 
permitted transduction of either donor-derived dendritic 
cells or EBV-LCL for use as antigen-presenting cells 
for CTL culture. Leen et al used this strategy to produce 
triviral (CMV, EBV, Adv-specific) CTLs, which were uti-
lized in a dose-escalation trial to treat 26 patients.17 No 
adverse effects were seen at doses ranging from 5×106 to 
1×108 cells/m2, and all patients were effectively protected 
against CMV, EBV, and Adv disease. However, although 
EBV-specific and CMV-specific CTLs showed persistence 
by interferon-gamma ELISPOT, Adv-specific CTLs were 
not detectable except in the setting of infection. A follow-up 
trial utilized Ad5f35-transduced EBV-LCL to produce EBV-
specific and Adv-specific CTL, which were infused into 13 
patients as prophylaxis or treatment of EBV and Adv follow-
ing HSCT.44 Although the products provided effective protec-
tion against EBV and Adv in vivo, Adv-specific CTLs were 
again not detectable except in the setting of Adv infection, 
suggesting that even at levels below the limits of detection by 
interferon-gamma ELISPOT, the Adv-specific CTL provided 
protection and was able to undergo expansion in the setting of 
viral infection. Ad5f35pp65-transduced dendritic cells were 
similarly used by Micklethwaite et al to produce CMV-specific 
and Adv-specific CTLs, which were clinically effective in 
12 patients who received infusions following HSCT.45 Only 
two subsequent episodes of CMV reactivation occurred in 
the setting of administration of prednisone at levels as low 
as 0.5 mg/kg/day. Blyth et al similarly treated 50 patients fol-
lowing HSCT with triviral (CMV, EBV, Adv-specific) CTLs 
which were derived by a mix of methods: ten were produced 
by pulsing donor dendritic cells with the HLA-A2-restricted 
CMV peptide NLVPMVATV and 40 were produced using 
Ad5f35pp65-transduced donor dendritic cells.46 Only five of 
the 50 patients developed CMV reactivations following CTL 
infusions, and one of these five required antiviral pharmaco-
therapy after being treated with steroids for acute GVHD.
Further protocol advances have validated the use of 15-mer 
peptide pools encompassing immunodominant viral antigens 
in place of viral transduction of antigen-presenting cells, thus 
removing the potential safety and regulatory barriers associ-
ated with use of viral vectors.33 The use of gas-permeable 
rapid-expansion (G-Rex) bioreactors has further simplified 
CTL culture.47 Gerdemann et al combined these two advances 
to develop a rapid protocol that yields CTL at clinical volumes 
in 10–12 days, and provided effective antiviral protection in 
ten patients who were infused following HSCT.34 The ongoing 
ARMS (Administration of Rapidly Generated Multivirus-
Specific Cytotoxic T-Lymphocytes for the Prophylaxis and 
Treatment of EBV, CMV, Adv, human herpesvirus 6 [HHV6], 
and BK virus infections post Allogeneic Stem Cell Transplant; 
NCT01570283) study has further modified this rapid protocol 
to produce five virus-specific CTL from a monoculture.
Gerdemann et al have further modified the rapid CTL 
protocol by utilizing nucleofection of DNA plasmids con-
taining viral epitopes into donor-derived dendritic cells.48 
The resulting CTL cultures showed antiviral activity in vitro 
by interferon-gamma ELISPOT and Cr51 cytotoxicity assays 
comparable with that of similar products derived via stimula-
tion with 15-mer peptide pools for the same viral epitopes.
Adverse events following administration of ex vivo 
cultured CTL products in 381 infusions for 180 patients on 
18 protocols were recently reviewed by the groups at Baylor 
College of Medicine.49 Twenty-four mild adverse events were 
reported within 6 hours of infusion, with nausea and vomiting 
being most common, and 22 nonserious adverse events (fever, 
chills, nausea) occurring within 24 hours. No significant 
GVHD was attributable to CTL infusion. The only significant 
complications of CTL therapy have been rare reports of sys-
temic inflammatory responses following EBV-CTL therapy 
in patients with bulky EBV+ lymphoma. Blyth et al reported 
that seven cases of acute GVHD occurred following CTL 
infusion, although some were attributable to corticosteroid 
weaning prior to CTL infusion, and additionally the authors 
noted that the degree of HLA mismatch was greater in patients 
who received CTL therapy versus controls.46
Recent developments
Third-party CTL use, expanded viral 
targets, T-cell receptor gene transfer,  
and CTL manufacture from pathogen-
naïve donors
Until recently, the selection or culture of antipathogen 
CTLs was dependent on the presence of pathogen-specific 
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memory T-cells in donor blood. These protocols failed to help 
recipients of pathogen-naïve stem cell products, a population 
that has been well described to be at increased risk of viral 
infection following HSCT.
One answer to this problem is the use of “off-the-shelf ” 
CTLs derived from third-party donors. This approach has 
been successfully used in several prior studies.50,51 Barker 
et al successfully treated two patients with refractory 
EBV-induced post-transplant lymphoproliferative disease 
following cord blood transplantation with third-party EBV-
specific CTLs.50 Leen et al utilized a bank of 32 CTL lines 
with characterized activity against EBV, CMV, and Adv to 
identify matched lines for 50 patients with refractory viral 
infections.51 These infusions resulted in antiviral responses 
in 74%, 78%, and 67% of those with CMV, Adv, and EBV, 
respectively. This represents a dramatic improvement from 
the standard therapy response rate in eight patients for whom 
a matched line could not be found, who had a response rate 
of 13% and a mortality rate of 75%. In spite of only partial 
HLA matching (1–4 loci), only two patients developed grade 
I GVHD. The lower rate of response against EBV relative 
to CMV and Adv may be reflective of a greater breadth of 
immunodominant epitopes that differ by MHC types, which 
complicates the task of selecting the ideal third-party line 
with both antiviral activity and proper MHC restriction.
Third-party CTL treatment has also been successful using 
selection methodology. Uhlin et al used pentamer selection to 
produce anti-viral CTL specific for CMV, EBV, or Adv from 
related third-party donors for six patients with refractory 
viral infections (four with CMV, and one each with EBV and 
Adv).52 Five of six patients had partial or complete responses. 
Notably, an infant with severe combined immunodeficiency 
was treated prior to cord blood transplantation with CMV-CTL 
derived from her mother, with a ten-fold reduction in her CMV 
DNA level. Wy and Qasim used interferon-gamma selection to 
manufacture Adv-CTL from related third-party donors to treat 
two patients who underwent HSCT and subsequently devel-
oped Adv viremia.53 Although treatment successfully cleared 
the Adv infection in one patient, she developed grade III skin 
and liver GVHD.54 Curiously, cytogenetic studies of liver tis-
sue showed infiltration with T-cells from the original HSCT 
donor but not the CTL donor. The authors postulated that this 
was due to a “bystander” effect of CTLs on the HSCT donor 
cells; however, such an effect has not been seen in larger trials 
utilizing third-party CTL therapy.
A small number of other viruses have been targeted via 
adoptive immunotherapy. John Cunningham virus (JCV) is 
an ubiquitous polyoma virus which can cause progressive 
multifocal leukoencephalopathy, a devastating neurologic 
disease, in patients who are profoundly immunocompromised, 
 including recipients of HSCT or solid organ transplants and 
patients with advanced human immunodeficiency virus 
or primary immunodeficiency disorders. Balduzzi et al 
described the use of donor-derived JCV-specific CTL in a 
14-year-old patient who developed progressive multifocal 
leukoencephalopathy in the setting of prolonged steroid 
treatment for GVHD following HSCT.55 These CTL were 
manufactured using 15-mer peptide pools encompassing the 
JCV antigens VP1 and LT, and were cultured for 26 days. The 
patient received two doses of JCV-specific CTLs, and had a 
remarkable and sustained improvement, including clearance 
of JCV-DNA from the cerebrospinal fluid and substantial 
improvements in his neurologic status.
Although not a frequent problem following HSCT, human 
papillomavirus (HPV) is not an uncommon late complica-
tion of HSCT, particularly in patients treated for primary 
immunodeficiency disorders. HPV has also been evaluated 
in preclinical studies as a potential target for CTL therapy. 
Ramos et al have described the use of peptide pools span-
ning the HPV E6 and E7 proteins to generate HPV-specific 
CTLs from patients with oropharyngeal or cervical cancer, 
many of which arise due to HPV16 infection.56 The resulting 
CTLs showed specific activity against HPV E6 and E7, and 
also showed antitumor activity against CaSki, an HPV16 
cervical cancer cell line.
Several studies have explored the possibility of trans-
ducing CTL with a T-cell antigen receptor of known viral 
specificity.57–59 This offers a novel strategy to develop CTL 
from pathogen-naïve donors, but imposes the additional regu-
latory requirements of transgenic technology. Additionally, 
the use of a single antiviral T-cell antigen receptor may risk 
antigenic escape by the pathogen. Nonetheless, a current 
trial of transgenic CTL utilizing a retroviral vector with a 
CMV-specific T-cell antigen receptor is being conducted in 
the UK by Emma Morris (principal investigator).60
An important landmark in the field of adoptive immuno-
therapy has been the successful development of virus-specific 
CTLs from virus-naïve donors. Hanley et al first demonstrated 
that CTL could be produced in a 20% fraction from cord blood 
using donor-derived dendritic cells and an EBV-lymphoblas-
toid cell line as antigen-presenting cells, and Ad5f35pp65 
transduction as a source of CMV and Adv antigens.16 The 
resulting cell lines had specific antiviral activity against CMV, 
EBV, and Adv in interferon-gamma ELISPOT analysis as well 
as Cr51 cytotoxicity assays, with no evidence of alloreactivity. 
Curiously, epitope mapping showed that the immunodominant 
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epitopes recognized by cord blood-derived CTLs differed 
from CTLs manufactured from CMV-seropositive and EBV-
seropositive adult donors, with the HLA-A2 restricted epitope 
NLVPMVATV notably absent in the cord blood-derived lines. 
Despite this finding, CTLs manufactured from cord blood have 
been used successfully in 12 cord blood transplant recipients 
to date in the ongoing ACTCAT (Safety, Toxicity and MTD 
of One Intravenous IV Injection of Donor CTLs Specific for 
CMV and Adenovirus; NCT00880789) trial.
Most recently, Hanley et al have successfully manufac-
tured multiviral CTLs from CMV-naïve adult donors.35 To do 
so, CMV-CTLs were produced from CD45RA+ naïve T-cells 
isolated via column selection, and stimulated by donor den-
dritic cells pulsed with CMV 15-mer peptide pools. Preclini-
cal data suggest that they have similar antiviral activity, and 
the current MUSTAT (Multivirus-Specific Cytotoxic T-Lym-
phocytes for the Prophylaxis and Treatment of EBV, CMV, 
and Adenovirus Infections post Allogeneic Stem Cell Trans-
plant; NCT01945814) trial will seek to compare the clinical 
efficacy of CTLs derived from CMV-seropositive versus 
CMV-naïve donors.
Anti-fungal CTLs
Fungal infections are a well described risk after HSCT. 
The importance of Th17 immunity in controlling Candida 
infections has been well demonstrated by forms of pri-
mary immunodeficiency such as Hyperimmunoglobulin E 
 syndrome and chronic mucocutaneous candidiasis, as well 
as human immunodeficiency virus infection.61,62 The impor-
tance of T-cell immunity in defense against invasive asper-
gillosis and mucormycosis is less clear, while their ties to 
innate defense (most notably neutrophil function) are well 
established. Interestingly, a recent study of patients with 
chronic granulomatous disease showed that they have abun-
dant Aspergillus-specific T-cells with increased interferon-
gamma production compared with healthy controls.63 Despite 
these uncertainties, fungal infections may be a valid target for 
treatment via adoptive immunotherapy after HSCT.
Several preclinical studies have been successful in devel-
oping CTLs with activity against Candida, Aspergillus, and 
Rhizopus species (Table 2). Beck et al successfully produced 
Aspergillus-specific CTLs by stimulation of PBMCs with 
antigens from Aspergillus extracts, followed by interferon-
gamma selection and culture.64 The resulting population 
was predominantly CD4+ memory (CD45RO+) cells, but 
demonstrated interferon-gamma production in response 
to several species of Aspergillus as well as Penicillium. 
The authors also showed that these T-cells enhanced hyphal 
damage by neutrophils and antigen-presenting cells in vitro. 
Tramsen et al similarly used interferon-gamma selection 
following stimulation with cellular extracts from Candida 
albicans, Aspergillus fumigatus, and Rhizopus oryzae to 
produce multifungal-specific CTL lines, which were also 
almost exclusively CD4+ CD45RO+ HLA-DR+.65 These 
lines displayed pathogen-specific activation markers (inter-
feron-gamma CD154, tumor necrosis factor-alpha) and also 
enhanced oxidative activity of neutrophils when coincubated 
with antigen and antigen-presenting cells and tested via the 
123-dihydrorhodamine assay. Khanna et al described a novel 
selection method based on upregulation of CD154 to produce 
multipathogen-specific T-cells against CMV, EBV, Adv, Can-
dida, and Aspergillus.66 Donor PBMCs were incubated with 
peptide libraries from CMV-pp65, EBV-LMP2, Adv-Hexon, 
Candida MP65, and a 15-mer peptide from Aspergillus CRF1. 
Following 14 days of culture, the authors showed pathogen-
specific interferon-gamma production, proliferation, and 
cytotoxicity in vitro. Although these results are intriguing, 
there are very limited data regarding the relative importance 
of MP65 and CRF1 in antifungal immunity.67,68
As of the time of this review, only one clinical trial of 
anti-fungal CTLs has been published. Perruccio et al devel-
oped CTLs via stimulation of donor PBMCs with inactivated 
conidia from A. fumigatus, followed by several weeks of 
culture, resulting in clonal CD4+ CTLs with anti-Aspergillus 
activity by interferon-gamma ELISPOT.69 Clinical use of 
these lines in patients with pulmonary aspergillosis resulted 
Table 2 Preclinical studies of novel antipathogen T-cell therapies
Study Pathogen 
specificity
Donor Methodology
Beck et al64 Aspergillus Healthy  
donors
Interferon-gamma 
selection after 
stimluation of PBMCs 
with Aspergillus extracts
Khanna  
et al66
Aspergillus,  
Candida, 
Rhinopus
Healthy  
donors
CD154 selection after 
stimulation of PBMCs 
with fungal extracts
Gerdemann  
et al34
CMv/eBv/Adv/ 
HHv6/RSv/ 
BK/influenza
Healthy  
donors
Nucleofection or 
Pepmix stimulation of 
DCs
Ramos  
et al56
HPv13 Cervical or 
nasopharyngeal 
cancer patients
Pepmix stimulation of 
DCs
Tramsen  
et al65
Aspergillus,  
Candida, 
Rhinopus
Healthy  
donors
Interferon-gamma 
selection after 
stimluation of PBMCs 
with fungal extracts
Abbreviations: Adv, adenovirus; CMv, cytomegalovirus; DCs, dendritic cells; 
eBv, epstein Barr virus; PBMCs, peripheral blood mononuclear cells; HHv, human 
herpesvirus 6; HPv, human papillomavirus; RSv, respiratory syncytial virus. 
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in  survival of eight of nine patients treated, compared with 
a survival rate of 7/13 in patients with aspergillosis who did 
not receive infusions. There was no difference in the length of 
antifungal therapy required for survivors in the two groups.
Although these studies are intriguing, several key issues 
require attention before anti-fungal CTL trials begin to catch 
up with their antiviral brethren. First, a better understanding of 
the immunodominant T-cell targets for various fungal species 
is needed. Second, standardized Good Manufacturing Practice-
compliant fungal antigen sources are necessary to allow consis-
tency and valid comparisons between future clinical trials.
Future of CTL therapy
expanding the breadth of monoculture 
CTL lines: is there an antigen limit?
As manufacture of CTLs expands to include more pathogens 
in a single culture, the possibility of antigenic competition 
between the different pathogen-specific T-cells has caused 
many to question the limits of CTL monocultures. This 
concern has certainly been validated in attempts to produce 
multivirus-specific CTLs from donors who are CMV-naïve, in 
which the resulting culture is dominated by memory-derived 
EBV-specific and Adv-specific T-cells. Although the relative 
proportions of individual virus-specific CTLs decrease as the 
number of antigens increases, this has not seemed to impact 
the efficacy of these products in clinical trials. Recent studies 
have challenged the upper antigen limit of CTL monoculture, 
as Gerdemann et al successfully produced CTLs specific 
for seven viruses (CMV, EBV, Adv, BK, HHV6, respiratory syn-
cytial virus (RSV), and influenza) utilizing peptide pools for 15 
antigens, and demonstrated specific activity against all targeted 
viruses via interferon-gamma ELISPOT.34 As additional preclini-
cal studies attempt to add further pathogens to monoculture, it 
remains to be seen whether an increased number of targets will 
compromise specific CTL function or persistence in vivo.
engineering resistance  
to immunosuppression
The need for immunosuppressive medications is common in 
recipients of HSCT, and unfortunately the use of these drugs 
also suppresses CTL products. Most existing protocols require 
recipients to be receiving less than 0.5 mg/kg/day prednisone 
and at least 30 days out from any anti-T-cell serotherapy in 
order to receive a CTL infusion. Calcineurin inhibitors such 
as cyclosporin A, tacrolimus, or sirolimus would similarly 
impact the clinical benefits of CTL at therapeutic doses.
One answer to this problem is to produce genetically 
modified CTLs that have resistance to immunosuppressive 
medications. Several recent studies have successfully 
demonstrated the viability of this concept. De Angelis et al 
produced EBV-specific CTLs with resistance to tacrolimus 
by knockdown of FKBP12 via a retrovirally-transduced 
specific siRNA.70 Transduction of CTLs did not impact 
antiviral activity, and the cells showed activity in a mouse 
EBV-lymphoma model in the presence of tacrolimus. Brewin 
et al similarly produced EBV-specific CTLs with resistance 
to both cyclosporin A and tacrolimus by direct mutation of 
calcineurin.71 The mutation had no impact on the phenotype or 
antiviral activity of the CTL in vitro, and mutated cells showed 
a growth advantage in the presence of calcineurin inhibitors.
Although similarly modified cells have not been used 
clinically to date, they have great potential in treating both 
HSCT and solid organ transplant recipients. Future exten-
sion of these studies could potentially allow production of 
CTLs with resistance to monoclonal biologic agents such 
as alemtuzumab.
Conclusion
With several hundred patients having been treated success-
fully, antipathogen CTLs have been established as a safe and 
highly effective therapy following HSCT. Further studies to 
identify preserved viral T-cell epitopes, probe the antigen 
limits in CTL monoculture, and test the clinical efficacy of 
immunosuppressive-resistant CTLs will further broaden the 
usefulness of this therapy. As rapid advances in protocols 
and multiple available methods of manufacture broaden the 
availability of this therapy, in time CTL therapy may become 
the standard of care following HSCT.
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